Burnett Patrick sold $30K of ARQT

Burnett Patrick (EVP, Chief Medical Officer) sold 943 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $31.86 on 2026-11-02.

Original reporting
SEC EDGAR · Burnett Patrick
Published Nov 4, 2026, 11:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Bearish
medium confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTBearishLow
01

Why it matters

The disclosed sale provides fresh, primary information but is modest in scale, offering limited trading impetus.

02

Market read

A small insider sell that may cause slight short‑term pressure but is unlikely to drive significant market moves.

03

What to watch

The transaction size is small relative to total holdings and may not affect liquidity.

Relevance 3/10Novelty 3/10Timing: post‑market filing on 2026‑11‑04

Background

Form 4 filing from the SEC discloses an insider transaction by Arcutis Biotherapeutics' EVP and Chief Medical Officer.

Company-level read

Ticker impact

$ARQTBearishMedium confidence
Context

CFO Burnett Patrick sold 943 shares of Arcutis Biotherapeutics for $30K, reducing his stake to 116,649 shares.

Expected impact

likely modest downward pressure as the market prices the insider sell.

Evidence & confidence

A C-level insider sold a modest amount; while not large, such sales often prompt short-term caution.

Market effects

Minimal impact on the biotech sector; insider sales are common and rarely shift sector sentiment.

No broader regional effect; the filing is company‑specific.

Limited relevance to global markets.

Counterpoint

The sale could be routine portfolio rebalancing and not indicative of future performance.

Key entities

  • Arcutis Biotherapeutics, Inc.

    US‑listed biotech company (ticker ARQT).

  • Burnett Patrick

    EVP, Chief Medical Officer of Arcutis Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.